{"url":"https://newsforagent.com/news/2026-10-18/incyte-esmo-2026-oncology-data","markdown_url":"https://newsforagent.com/news/2026-10-18/incyte-esmo-2026-oncology-data.md","title":"Incyte to Present KRAS G12D Oncology Data at ESMO 2026","headline":"Incyte to Present KRAS G12D and TGFβR2×PD-1 Data Informing Phase 3 Programs at ESMO 2026","description":"Incyte will present KRAS G12D and TGFβR2×PD-1 oncology data at ESMO 2026 and host an investor webcast on October 26 to discuss the results and portfolio updates.","section":"Research & Clinical Trials","published_at":"2026-10-18T22:33:57+00:00","modified_at":"2026-10-18T22:33:57+00:00","author":"News Desk","key_takeaways":["Incyte will present new oncology data at ESMO 2026, including KRAS G12D and TGFβR2×PD-1 programs that inform ongoing registrational Phase 3 studies.","An investor webcast is scheduled for October 26 to discuss key data and portfolio updates.","Incyte's third quarter financial results conference call and webcast is set for October 29, 2026, at 8:00 a.m. ET."],"companies":[{"name":"Incyte","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0003zwi/incyte","website":"http://www.incyte.com"}],"source":{"publisher":"TradingView","title":"Incyte (INCY) To Present Oncology Data Informing Phase 3 Programs at ESMO 2026","url":"https://www.tradingview.com/news/tradingview:06a6b09f59a13:0-incyte-incy-to-present-oncology-data-informing-phase-3-programs-at-esmo-2026/"},"other_sources":[],"tags":["Research & Clinical Trials","Incyte"],"body_markdown":"[Incyte](https://akta.pro/company-profiles/0003zwi/incyte) will present new oncology data at ESMO 2026, including KRAS G12D and TGFβR2×PD-1 programs that the company says inform ongoing registrational Phase 3 studies. [TradingView](https://www.tradingview.com/news/tradingview:06a6b09f59a13:0-incyte-incy-to-present-oncology-data-informing-phase-3-programs-at-esmo-2026/) reported the presentation plans and an investor webcast set for October 26 to discuss key data and portfolio updates.\n\n## Incyte's ESMO 2026 Data and Webcast Plans\n\nIncyte said the ESMO 2026 presentations will include rapid oral data across its pipeline. The disclosed programs cover a KRAS G12D inhibitor with readouts in colorectal cancer and pancreatic ductal adenocarcinoma, a TGFβR2×PD-1 bispecific in microsatellite stable colorectal cancer, and CDK2 combination data in recurrent ovarian cancer.\n\nIncyte is a publicly traded biopharmaceutical company that discovers, develops, and commercializes small-molecule and biologic therapies for serious unmet needs in hematology, oncology, and inflammation/autoimmunity, operating commercially in 19 countries with a global specialty distribution and physician field-sales model, according to akta.pro [company records](https://akta.pro/company-data).\n\nThe company said the data inform ongoing registrational Phase 3 studies. An investor webcast is scheduled for October 26 to discuss key data and portfolio updates.\n\n## Incyte's Pipeline Deals Behind the ESMO Readouts\n\nIncyte's recent pipeline activity includes a June 2026 agreement to acquire Vega Therapeutics, a Star Therapeutics subsidiary, for $1.25 billion upfront plus up to $750 million in sales milestones, adding VGA039, a Phase 3 monoclonal antibody for von Willebrand disease, according to company records. In April 2026, Incyte entered a clinical collaboration with Adagene to evaluate muzastotug (ADG126), a masked anti-CTLA-4 antibody, in combination with INCA33890, Incyte's TGFβR2×PD-1 bispecific antibody, in patients with microsatellite stable colorectal cancer.\n\nIn May 2026, Incyte expanded its AI drug-discovery collaboration with Genesis Molecular AI from two to at least five targets for $120 million upfront, comprising $80 million cash plus $40 million equity, and up to $232 million per target in milestones, with total deal value potentially exceeding $1 billion.\n\n## Incyte's Recent Approvals and Financial Calendar\n\nThe FDA approved Atebrioz, an oral ALK2 inhibitor for Fibrodysplasia Ossificans Progressiva, and granted Incyte a Rare Pediatric Disease Priority Review Voucher, Simply Wall St reported on October 9, 2026. Incyte scheduled its third quarter financial results conference call and webcast for October 29, 2026, at 8:00 a.m. ET, with the press release set for 7:00 a.m. ET, Business Wire Blog reported on October 8, 2026.\n\n## Incyte's Next Dated Steps\n\nIncyte's investor webcast on the ESMO 2026 data is set for October 26. The company's third quarter financial results conference call and webcast is scheduled for October 29, 2026, at 8:00 a.m. ET. Incyte will honor eight winners of its 2026 MPN Heroes recognition program on December 11, 2026, at the ASH meeting in New Orleans, FinancialContent Business Page reported on October 13, 2026.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}